Literature DB >> 17868948

Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution.

Brinda Balakrishnan1, John F Dooley, Gregory Kopia, Elazer R Edelman.   

Abstract

Millions of patients worldwide have received drug-eluting stents to reduce their risk for in-stent restenosis. The efficacy and toxicity of these local therapeutics depend upon arterial drug deposition, distribution, and retention. To examine how administered dose and drug release kinetics control arterial drug uptake, a model was created using principles of computational fluid dynamics and transient drug diffusion-convection. The modeling predictions for drug elution were validated using empiric data from stented porcine coronary arteries. Inefficient, minimal arterial drug deposition was predicted when a bolus of drug was released and depleted within seconds. Month-long stent-based drug release efficiently delivered nearly continuous drug levels, but the slow rate of drug presentation limited arterial drug uptake. Uptake was only maximized when the rates of drug release and absorption matched, which occurred for hour-long drug release. Of the two possible means for increasing the amount of drug on the stent, modulation of drug concentration potently impacts the magnitude of arterial drug deposition, while changes in coating drug mass affect duration of release. We demonstrate the importance of drug release kinetics and administered drug dose in governing arterial drug uptake and suggest novel drug delivery strategies for controlling spatio-temporal arterial drug distribution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868948      PMCID: PMC2702153          DOI: 10.1016/j.jconrel.2007.06.025

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  32 in total

1.  Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel.

Authors:  Andrew D Levin; Neda Vukmirovic; Chao-Wei Hwang; Elazer R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

2.  In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices.

Authors:  Frank Alexis; Subbu S Venkatraman; Santosh Kumar Rath; Freddy Boey
Journal:  J Control Release       Date:  2004-07-23       Impact factor: 9.776

3.  Effects of the non-Newtonian viscosity of blood on flows in a diseased arterial vessel. Part 1: Steady flows.

Authors:  Y I Cho; K R Kensey
Journal:  Biorheology       Date:  1991       Impact factor: 1.875

4.  Controlled release and magnetically modulated release systems for macromolecules.

Authors:  R Langer; L Brown; E Edelman
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

5.  The blood rheology of man and various animal species.

Authors:  T M Amin; J A Sirs
Journal:  Q J Exp Physiol       Date:  1985-01

6.  One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

7.  Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial.

Authors:  Alexandra J Lansky; Ricardo A Costa; Gary S Mintz; Yoshihiro Tsuchiya; Mark Midei; David A Cox; Charles O'Shaughnessy; Robert A Applegate; Louis A Cannon; Michael Mooney; Anthony Farah; Mark A Tannenbaum; Steven Yakubov; Dean J Kereiakes; S Chiu Wong; Barry Kaplan; Ecaterina Cristea; Gregg W Stone; Martin B Leon; William D Knopf; William W O'Neill
Journal:  Circulation       Date:  2004-04-12       Impact factor: 29.690

8.  Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.

Authors:  David R Holmes; Martin B Leon; Jeffrey W Moses; Jeffrey J Popma; Donald Cutlip; Peter J Fitzgerald; Charles Brown; Tim Fischell; Shing Chiu Wong; Mark Midei; David Snead; Richard E Kuntz
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

9.  Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.

Authors:  Jörg Hausleiter; Adnan Kastrati; Julinda Mehilli; Michael Vogeser; Dietlind Zohlnhöfer; Helmut Schühlen; Christoph Goos; Jürgen Pache; Franz Dotzer; Gisela Pogatsa-Murray; Josef Dirschinger; Uwe Heemann; Albert Schömig
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

10.  Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial.

Authors:  Anthony Gershlick; Ivan De Scheerder; Bernard Chevalier; Amanda Stephens-Lloyd; Edoardo Camenzind; Christian Vrints; Nicolaus Reifart; Luc Missault; Jean-Jacques Goy; Jeffrey A Brinker; Albert E Raizner; Philip Urban; Alan W Heldman
Journal:  Circulation       Date:  2004-01-26       Impact factor: 29.690

View more
  33 in total

1.  Smooth muscle cells orchestrate the endothelial cell response to flow and injury.

Authors:  Mercedes Balcells; Jordi Martorell; Carla Olivé; Marina Santacana; Vipul Chitalia; Angelo A Cardoso; Elazer R Edelman
Journal:  Circulation       Date:  2010-05-10       Impact factor: 29.690

2.  Stent elution rate determines drug deposition and receptor-mediated effects.

Authors:  Abraham R Tzafriri; Adam Groothuis; G Sylvester Price; Elazer R Edelman
Journal:  J Control Release       Date:  2012-05-26       Impact factor: 9.776

3.  Drug deposition in coronary arteries with overlapping drug-eluting stents.

Authors:  Farhad Rikhtegar; Elazer R Edelman; Ufuk Olgac; Dimos Poulikakos; Vartan Kurtcuoglu
Journal:  J Control Release       Date:  2016-07-16       Impact factor: 9.776

4.  A finite element study on variations in mass transport in stented porcine coronary arteries based on location in the coronary arterial tree.

Authors:  Joseph T Keyes; Bruce R Simon; Jonathan P Vande Geest
Journal:  J Biomech Eng       Date:  2013-06       Impact factor: 2.097

5.  Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug.

Authors:  Wenda C Carlyle; James B McClain; Abraham R Tzafriri; Lynn Bailey; Brett G Zani; Peter M Markham; James R L Stanley; Elazer R Edelman
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

6.  Modeling and analysis of drug-eluting stents with biodegradable PLGA coating: consequences on intravascular drug delivery.

Authors:  Xiaoxiang Zhu; Richard D Braatz
Journal:  J Biomech Eng       Date:  2014-11       Impact factor: 2.097

7.  Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis.

Authors:  Abraham R Tzafriri; Fernando Garcia-Polite; Brett Zani; James Stanley; Benny Muraj; Jennifer Knutson; Robert Kohler; Peter Markham; Alexander Nikanorov; Elazer R Edelman
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

8.  Location-dependent coronary artery diffusive and convective mass transport properties of a lipophilic drug surrogate measured using nonlinear microscopy.

Authors:  Joseph T Keyes; Bruce R Simon; Jonathan P Vande Geest
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

Review 9.  Factors that affect mass transport from drug eluting stents into the artery wall.

Authors:  Barry M O'Connell; Tim M McGloughlin; Michael T Walsh
Journal:  Biomed Eng Online       Date:  2010-03-09       Impact factor: 2.819

10.  Luminal flow amplifies stent-based drug deposition in arterial bifurcations.

Authors:  Vijaya B Kolachalama; Evan G Levine; Elazer R Edelman
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.